New Republic November 19, 2021
Natalie Shure

New medicines are on the way in the fight against the pandemic, but these life-saving drugs might get trapped in a maze of bad policy.

Is a new dawn breaking in the fight against the global pandemic? Now that two major pharmaceutical firms have filed for emergency use authorization for new antiviral pills, we may soon have some valuable arrows in our quiver to fight Covid-19. Per company reports, a short course of Merck’s molnupiravir regimen reduces hospitalizations among infected patients by 50 percent; Pfizer’s Paxlovid curbed admissions by an eye-popping 89 percent—and neither treatment group reported any deaths. The Biden administration has reportedly pumped several billion dollars into the effort, ordering several million courses of each at around $700 a...

Today's Sponsors

Patient Bond
Institute for Healthcare Improvement

Today's Sponsors

Oliver Wyman
Patient Bond

Today's Sponsor

Patient Bond

Topics: Govt Agencies, Healthcare System, Patient / Consumer, Provider, Public Health / COVID
URAC CEO talks virtual care access, tele-mental health, post-COVID regs
Telehealth use after pandemic is uncertain, study finds
AI models can predict individual risk of hospitalization for COVID using HIE data
US senators aim to reform health agencies before next pandemic
Faust Files: Are We Now Better Prepared for the Next Pandemic?